{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T10:51:05Z","timestamp":1780656665707,"version":"3.54.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T00:00:00Z","timestamp":1687132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Biologicals SA"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is growing consensus that coronavirus disease 2019 booster vaccines may be coadministered with other age-appropriate vaccines. Adding to the limited available data supporting coadministration, especially with adjuvanted vaccines, could enhance vaccine coverage in adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this phase 3, randomized, open-label study, eligible adults aged \u226550 years were randomly assigned (1:1) to receive mRNA-1273 (50 \u00b5g) booster vaccination and a first dose of recombinant zoster vaccine (RZV1) 2 weeks apart (Seq group) or concomitantly (Coad group). The second RZV dose (RZV2) was administered 2 months post-RZV1 in both groups. Primary objectives were noninferiority of anti\u2013glycoprotein E (gE) and anti\u2013spike protein antibody responses in the Coad group compared to the Seq group. Safety and further immunogenicity assessments were secondary objectives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 273 participants were randomized to the Seq group and 272 to the Coad group. Protocol-specified noninferiority criteria were met. The adjusted geometric mean concentration ratio (Seq\/Coad) was 1.01 (95% confidence interval [CI], .89\u20131.13) for anti-gE antibodies 1 month post-RZV2, and 1.09 (95% CI, .90\u20131.32) for anti\u2013spike antibodies 1 month post\u2013mRNA-1273 booster. No clinically relevant differences were observed in overall frequency, intensity, or duration of adverse events between the 2 study groups. Most solicited adverse events were mild\/moderate in intensity, each with median duration \u22642.5 days. Administration site pain and myalgia were the most frequently reported in both groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Coadministration of mRNA-1273 booster vaccine with RZV in adults aged \u226550 years was immunologically noninferior to sequential administration and had a safety and reactogenicity profile consistent with both vaccines administered sequentially.<\/jats:p>\n                    <jats:p>Clinical Trials Registration.\u2003NCT05047770.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciad361","type":"journal-article","created":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T16:00:16Z","timestamp":1687190416000},"page":"1238-1246","source":"Crossref","is-referenced-by-count":8,"title":["No Immunological Interference or Safety Concerns When Adjuvanted Recombinant Zoster Vaccine Is Coadministered With a Coronavirus Disease 2019 mRNA-1273 Booster Vaccine in Adults Aged 50 Years and Older: A Randomized Trial"],"prefix":"10.1093","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1076-5280","authenticated-orcid":false,"given":"Abdi","family":"Naficy","sequence":"first","affiliation":[{"name":"Clinical Sciences, GSK, Rockville , Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7663-7409","authenticated-orcid":false,"given":"Adrienne","family":"Kuxhausen","sequence":"additional","affiliation":[{"name":"Biostatistics, GSK , Rockville, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1465-4529","authenticated-orcid":false,"given":"Paola","family":"Pirrotta","sequence":"additional","affiliation":[{"name":"Safety Evaluation & Risk Management, GSK , Wavre , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0907-0817","authenticated-orcid":false,"given":"Brett","family":"Leav","sequence":"additional","affiliation":[{"name":"Infectious Disease Development, Moderna, Inc , Cambridge, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7083-2182","authenticated-orcid":false,"given":"Jacqueline","family":"Miller","sequence":"additional","affiliation":[{"name":"Infectious Disease Development, Moderna, Inc , Cambridge, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5027-4753","authenticated-orcid":false,"given":"Kate","family":"Anteyi","sequence":"additional","affiliation":[{"name":"Clinical Safety & Pharmacovigilance, Moderna, Inc , Cambridge, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5032-8333","authenticated-orcid":false,"given":"Jasur","family":"Danier","sequence":"additional","affiliation":[{"name":"Clinical Sciences, GSK, Rockville , Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2532-0505","authenticated-orcid":false,"given":"Thomas","family":"Breuer","sequence":"additional","affiliation":[{"name":"Global Health, GSK , Tres Cantos , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6576-1981","authenticated-orcid":false,"given":"Agnes","family":"Mwakingwe-Omari","sequence":"additional","affiliation":[{"name":"Clinical Sciences, GSK, Rockville , Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,19]]},"reference":[{"key":"2023111417431183000_ciad361-B1","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.15585\/mmwr.mm7038e1","article-title":"Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions\u2014United States, March\u2013August 2021","volume":"70","author":"Self","year":"2021","journal-title":"Morb Mortal Wkly Rep"},{"key":"2023111417431183000_ciad361-B2","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression","volume":"399","author":"Feikin","year":"2022","journal-title":"Lancet"},{"key":"2023111417431183000_ciad361-B3","author":"Centers for Disease Control and Prevention","year":"2022"},{"key":"2023111417431183000_ciad361-B4","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.15585\/mmwr.mm7145a2","article-title":"Interim recommendations from the Advisory Committee on Immunization Practices for the use of bivalent booster doses of COVID-19 vaccines\u2014United States, October 2022","volume":"71","author":"Rosenblum","year":"2022","journal-title":"Morb Mortal Wkly Rep"},{"key":"2023111417431183000_ciad361-B5","author":"World Health Organization Regional Office for Europe"},{"key":"2023111417431183000_ciad361-B6","author":"Our World in Data"},{"key":"2023111417431183000_ciad361-B7","author":"Avalere Health","year":"2022"},{"key":"2023111417431183000_ciad361-B8","author":"Centers for Disease Control and Prevention"},{"key":"2023111417431183000_ciad361-B9","author":"UK Health Security Agency","year":"2023"},{"key":"2023111417431183000_ciad361-B10","author":"World Health Organization","year":"2022"},{"key":"2023111417431183000_ciad361-B11","author":"Australia Government Department of Health and Aged Care","year":"2022"},{"key":"2023111417431183000_ciad361-B12","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S2213-2600(21)00557-9","article-title":"Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged \u226565 years: a phase 2, randomised, open-label study","volume":"10","author":"Izikson","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2023111417431183000_ciad361-B13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S2213-2600(21)00409-4","article-title":"Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial","volume":"10","author":"Toback","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2023111417431183000_ciad361-B14","author":"Centers for Disease Control and Prevention","year":"2021"},{"key":"2023111417431183000_ciad361-B15","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"2023111417431183000_ciad361-B16","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"2023111417431183000_ciad361-B17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jama.2019.9053","article-title":"Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial","volume":"322","author":"Bastidas","year":"2019","journal-title":"JAMA"},{"key":"2023111417431183000_ciad361-B18","author":"European Medicines Agency","year":"2018"},{"key":"2023111417431183000_ciad361-B19","doi-asserted-by":"crossref","first-page":"80","DOI":"10.15585\/mmwr.mm7103a2","article-title":"Use of recombinant zoster vaccine in immunocompromised adults aged \u226519 years: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2022","volume":"71","author":"Anderson","year":"2022","journal-title":"Morb Mortal Wkly Rep"},{"key":"2023111417431183000_ciad361-B20","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/all.14657","article-title":"Risk factors for severe and critically ill COVID-19 patients: a review","volume":"76","author":"Gao","year":"2021","journal-title":"Allergy"},{"key":"2023111417431183000_ciad361-B21","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"2023111417431183000_ciad361-B22","author":"European Medicines Agency","year":"2023"},{"key":"2023111417431183000_ciad361-B23","author":"US Food and Drug Administration"},{"key":"2023111417431183000_ciad361-B24","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","article-title":"Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older","volume":"217","author":"Cunningham","year":"2018","journal-title":"J Infect Dis"},{"key":"2023111417431183000_ciad361-B25","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/cis238","article-title":"Nomenclature for immune correlates of protection after vaccination","volume":"54","author":"Plotkin","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2023111417431183000_ciad361-B26","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","article-title":"Evidence for antibody as a protective correlate for COVID-19 vaccines","volume":"39","author":"Earle","year":"2021","journal-title":"Vaccine"},{"key":"2023111417431183000_ciad361-B27","doi-asserted-by":"crossref","DOI":"10.1126\/science.abj0299","article-title":"Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates","volume":"373","author":"Corbett","year":"2021","journal-title":"Science"},{"key":"2023111417431183000_ciad361-B28","author":"US Food and Drug Administration","year":"2023"},{"key":"2023111417431183000_ciad361-B29","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa2208343","article-title":"A bivalent Omicron-containing booster vaccine against Covid-19","volume":"387","author":"Chalkias","year":"2022","journal-title":"N Engl J Med"},{"key":"2023111417431183000_ciad361-B30","author":"US Food and Drug Administration","year":"2023"},{"key":"2023111417431183000_ciad361-B31","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.15585\/mmwr.mm7144a3","article-title":"Safety monitoring of bivalent COVID-19 mRNA vaccine booster doses among persons aged \u226512 years\u2014United States, 31 August\u201323 October 2022","volume":"71","author":"Hause","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciad361\/51047427\/ciad361.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/77\/9\/1238\/53403581\/ciad361.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/77\/9\/1238\/53403581\/ciad361.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T13:46:11Z","timestamp":1699969571000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/77\/9\/1238\/7202273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,19]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,6,19]]},"published-print":{"date-parts":[[2023,11,11]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad361","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.03.10.23286967","asserted-by":"object"}]},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11,1]]},"published":{"date-parts":[[2023,6,19]]}}}